Amylyx Pharmaceuticals Inc.
AMLX | NASDAQ
$32.39
-$0.02 (-0.06%)
At close: Sep 21, 2026, 4:00 PM ET
$32.45
+$0.06 (+0.19%)
Pre-market:
Sep 22, 2026, 5:18 AM ET
Market Data
Market Cap $3.6B
Enterprise Value $3.36B
Beta -0.21
Average Volume 2.08M
Shares Outstanding (Diluted) 111.2M
Shares Change YoY 24.75%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US03237H1014
Price Performance
Price Change 1M -16.2%
Price Change 3M 97.9%
Price Change 6M 134.2%
Price Change YTD 183.6%
Price Change 1Y 143.3%
Price Change 3Y 75.3%
Price Change 5Y 79.3%
1M CAGR (ann.) 34.0%
1Y CAGR (ann.) 153.8%
5Y CAGR (ann.) N/A
All-Time CAGR 13.2%
Valuation
PE Ratio -22.97
Forward PE N/A
PEG Ratio -0.39
Forward PEG 1.07
PS Ratio N/A
Forward PS 63.80
PB Ratio 15.06
P/FCF Ratio -28.42
P/Adj. FCF Ratio -23.29
P/OCF Ratio -28.41
EV/Sales N/A
EV/EBIT -22.35
EV/EBITDA -22.40
EV/FCF -26.48
Earnings Yield -4.3%
FCF Yield -3.5%
Adj. FCF Yield -4.3%
Financial Health
Net Cash $250.76M
Total Debt $5.26M
Cash & Short-Term Investments $250.76M
Total Assets $264.56M
Current Ratio 12.12
Quick Ratio 12.12
Debt / Equity Ratio 0.02
Debt / EBITDA -0.04
Debt / FCF -0.04
OCF / Debt -24.09
Interest Coverage 0.00
Altman Z-Score 79.90
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin 0.0%
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue 0.0%
SBC Impact (per share) -22.0%
Returns
Return on Assets -57.5%
Return on Equity -52.9%
Return on Invested Capital -66.3%
Return on Capital Employed -66.6%
Return on Tangible Assets -57.5%
Historical Growth (CAGR)
Revenue CAGR 3Y -150.1%
Revenue CAGR 5Y -19.6%
Revenue CAGR 10Y N/A
EPS CAGR 3Y 24.5%
EPS CAGR 5Y 7.2%
EPS CAGR 10Y N/A
FCF CAGR 3Y -28.6%
FCF CAGR 5Y -4.5%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 11
EPS Growth Next 3Y 85.8%
Revenue Growth Next 3Y N/A
Earnings Date Nov 4, 2026
EPS Estimate (next Q) -$0.38
EPS Growth Est (next Q) 2.7%
Revenue Est (next Q) $59.43K
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $52.20
Price Target Upside 61.2%
Cash Flow
Operating Cash Flow $-126.58M
Free Cash Flow $-126.72M
Adj. Free Cash Flow $-154.62M
FCF Per Share -$1.14
OCF Per Share -$1.14
OCF/S Ratio 0.0%
Income Statement
Revenue $0
Gross Profit $-20.06M
Operating Income $-162.1M
EBITDA $-149.78M
Net Income $-152.09M
EPS (Diluted) -$1.41
Revenue / Employee N/A
Profit / Employee $-1.12M
Employees 136
Add to Watchlist
Select watchlists to add or remove AMLX